Search

#Biotech
R
Reuters 2d

The departure of U.S. FDA Commissioner Dr. Marty Makary is seen as a positive shift amid turmoil in the biotech sector, yet analysts warn that the lack of steady leadership may lead to increased volatility and unpredictability within the agency until a permanent replacement is appointed. #Biotech #FDA #Leadership #US

Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms

Celine Halioua, the founder of Loyal, a biotechnology company developing a potential longevity drug for dogs, represents a growing trend in the pet-longevity market, where the intersection of human desires for longer pet lives and advancements in canine health sciences have led to significant investments, promising treatments, and an exploration of the implications for human aging research. #DogLongevity #PetCare #Biotechnology #US #TX #CA #UK

What if You Could Give Your Dog a Longer Life?

Scientists at Bristol Myers Squibb's Devens facility are utilizing artificial intelligence to monitor critical variables in the production of disease-fighting proteins, enhancing drug manufacturing efficiency by 40% and tackling shortages, while the company faces tough competition from China's rapidly advancing biotech sector and implements cost-cutting measures in light of patent expirations and the potential impact of AI on jobs in the industry. #ArtificialIntelligence #PharmaceuticalInnovation #Biotechnology #US #CN #TH

American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.

At the Bristol Myers Squibb facility in Devens, Massachusetts, scientists are leveraging artificial intelligence to enhance the production of genetically engineered proteins for disease treatment, improving drug output by 40% and allowing real-time intervention during the manufacturing process, while facing challenges in translating technological advancements into broader productivity gains compared to China's rapidly scaling biotech sector. #ArtificialIntelligence #Biotechnology #DrugDiscovery #US #CN #TH

American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.

Mark Zuckerberg and Priscilla Chan's Biohub is investing $500 million in a five-year initiative to create AI models of human cells, aiming to revolutionize disease research and treatment through open-access data while facing challenges in data scale and accuracy. #ArtificialIntelligence #Biotechnology #HealthInnovations #US #FR #DE #CN #JP #GB #IN

Can AI simulate human cells? Inside Mark Zuckerberg's plan